<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616731</url>
  </required_header>
  <id_info>
    <org_study_id>TXAvsDiosmin-IUDmenorrhagia</org_study_id>
    <nct_id>NCT02616731</nct_id>
  </id_info>
  <brief_title>Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD</brief_title>
  <official_title>Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of tranexamic acid and diosmin in reducing menstrual blood loss in
      women having Intra Uterine Contraceptive Device (IUD) and suffer from menorrhagia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The amount of reducing heavy menstrual flow will be calculated by the PBAC.</measure>
    <time_frame>the first 24hours</time_frame>
    <description>measure the bleeding rate will be by the pictorial blood assessment chart (PBAC).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diosmin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>kapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diosmin</intervention_name>
    <description>use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC</description>
    <arm_group_label>Diosmin</arm_group_label>
    <other_name>dycinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women complaining from an menorrhagia secondary to a current copper IUD use.

          -  Age: 20-40years.

          -  Menorrhagia , will be defined as a PBAC-Score greater than 100.

          -  No systemic causes of abnormal uterine bleeding as hypertension and hemorrhagic blood
             diseases.

          -  No other local causes of abnormal uterine bleeding as, (fibroid, adenomyosis, polyps).

          -  No drugs decreasing blood coagulation.

          -  Well fitted IUD not misplaced.

        Exclusion Criteria:

          -  Age &lt;20y and &gt;40y.

          -  Irregular menstrual cycle.

          -  Presence of systemic causes of abnormal uterine bleeding as hypertension and
             hemorrhagic blood diseases.

          -  Presence of other local causes of abnormal uterine bleeding as, (fibroid, adenomyosis,
             polyps).

          -  Taking drugs decrease blood coagulation.

          -  Misplaced IUD.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ahmed alanwar, MD</last_name>
    <phone>+201111486669</phone>
    <email>eladwar@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ahmed Alanwar</name>
      <address>
        <city>Cairo</city>
        <zip>11331</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ahmed alanwar, MD</last_name>
      <phone>+201111486669</phone>
      <phone_ext>002</phone_ext>
      <email>eladwar@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ahmed kotb, MD</last_name>
      <phone>+201008681999</phone>
      <phone_ext>002</phone_ext>
      <email>ahmedmkotp@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>November 25, 2015</last_update_submitted>
  <last_update_submitted_qc>November 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Alanwar</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

